To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Gene Therapy Market size was valued at USD 6.39 Billion in 2021 and is poised to grow from USD 7.60 Billion in 2022 to USD 38.34 Billion by 2030, at a CAGR of 19% during the forecast period (2023-2030).

The gene therapy market is highly competitive with a large number of players operating in the industry. The key players in the market are focusing on the development of new and advanced therapies to enhance their market presence. The gene therapy market is highly competitive, with a number of players focusing on the development of novel therapies for the treatment of a range of diseases. The market is expected to continue to grow in the coming years, driven by increasing investment in R&D and growing demand for new and advanced therapies for the treatment of rare and life-threatening diseases. 'Novartis International AG (Switzerland)', 'Pfizer Inc. (US)', 'Biogen Inc. (US)', 'Spark Therapeutics Inc. (US)', 'Sarepta Therapeutics Inc. (US)', 'bluebird bio-Inc. (US)', 'Gilead Sciences Inc. (US)', 'Amgen Inc. (US)', 'Regenxbio Inc. (US)', 'Krystal Biotech Inc. (US)', 'uniQure N.V. (Netherlands)', 'Avexis Inc. (US)', 'Orchard Therapeutics plc (UK)', 'Abeona Therapeutics Inc. (US)', 'Solid Biosciences Inc. (US)', 'Audentes Therapeutics Inc. (US)', 'Adaptimmune Therapeutics plc (UK)', 'Intellia Therapeutics Inc. (US)', 'Editas Medicine Inc. (US)', 'Precision BioSciences Inc. (US)'

Genetic disorders, such as spinal muscular atrophy, cystic fibrosis, and hemophilia, are on the rise worldwide. The increasing prevalence of these disorders is driving the growth of the gene therapy market, as gene therapies have shown promising results in the treatment of these disorders.

Increased focus on rare diseases: Gene therapy is becoming increasingly popular for the treatment of rare genetic disorders, which were previously ignored due to their low prevalence. For example, Zolgensma, a gene therapy for spinal muscular atrophy, was approved by the FDA in 2019 and has since become a popular treatment option. Similarly, Luxturna, a gene therapy for inherited retinal disease, was approved in 2017.

In 2022, North America emerged as the dominant region in the gene therapy market, contributing to over 65.0% of the overall revenue. It is projected to remain the largest routine manufacturer of gene therapy drugs during the forecast period, with increasing investments in R&D by companies of all sizes. The market is being driven by rising government investments and the growing prevalence of targeted diseases in the region, such as spinal muscular atrophy, affecting 10,000 to 25,000 individuals in the U.S. alone, according to the Spinal Muscular Atrophy Foundation.

Feedback From Our Clients

Global Gene therapy Market

Product ID: SQMIG35H2218